PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 10-Q

Item 5. Other Information Not applicable. ‎ 59 Table of Contents Item 6. Exhibits Incorporated by reference herein Exhibit ‎ Number Description Form Exhibit No. Filing Date 4.1 Indenture, dated February 16, 2021, between Pacific Biosciences of California, Inc. and U.S. Bank National Association, as Trustee 8-K 4.1 February 17, 2021 4.2 Form of 1.50% Convertible Senior Notes due 2028 (included in Exhibit 4.1) 8-K 4.1 February 17, 2021 10.1 Investment Agreement, dated as of February 9, 2021, between Pacific Biosciences of California, Inc. and SB Northstar LP 8-K 10.1 February 10, 2021 10.2+ Form of Change in Control and Severance Agreement for executive officers 10-K 10.14 February 26, 2021 10.3+ Amended Change in Control and Severance Agreement by and between the Registrant and Christian O. Henry dated February 3, 2021 10-K 10.17 February 26, 2021 10.4+ Letter Relating to Employment Terms by and between the Registrant and Mark Van Oene effective January 8, 2021 10-K 10.18 February 26, 2021 10.5+ Letter Relating to Employment Terms by and between the Registrant and Peter Fromen effective January 8, 2021 10-K 10.19 February 26, 2021 10.6+ Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder 8-K 10.1 April 19, 2021 10.7† Development and Commercialization Agreement by and between the Registrant and Invitae Corporation dated January 12, 2021 10-K 10.23 February 26, 2021 31.1 Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 32.1* Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 32.2* Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 101.INS XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Labels Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101) + Indicates management contract or compensatory plan † Certain confidential information contained in this Exhibit was omitted by means of marking such portions with brackets because the identified confidential information (i) is not material and (ii) would be competitively harmful if publicly disclosed. * The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing 60 Table of Contents Signatures Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. P ACIFIC B IOSCIENCES OF C ALIFORNIA , I NC . Date: May 6, 2021 By: /s/ S USAN G. Kim Susan G. Kim Chief Financial Officer Date: May 6, 2021 By: /s/ Eric E. Schaefer Eric E. Schaefer Vice President and Chief Accounting Officer 61